423 related articles for article (PubMed ID: 25056116)
1. Low-dose PTH increases osteoblast activity via decreased Mef2c/Sost in senescent osteopenic mice.
Saidak Z; Le Henaff C; Azzi S; Marty C; Marie PJ
J Endocrinol; 2014 Oct; 223(1):25-33. PubMed ID: 25056116
[TBL] [Abstract][Full Text] [Related]
2. Strontium ranelate rebalances bone marrow adipogenesis and osteoblastogenesis in senescent osteopenic mice through NFATc/Maf and Wnt signaling.
Saidak Z; Haÿ E; Marty C; Barbara A; Marie PJ
Aging Cell; 2012 Jun; 11(3):467-74. PubMed ID: 22321691
[TBL] [Abstract][Full Text] [Related]
3. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
[TBL] [Abstract][Full Text] [Related]
4. gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation.
Standal T; Johnson RW; McGregor NE; Poulton IJ; Ho PW; Martin TJ; Sims NA
J Endocrinol; 2014 Nov; 223(2):181-90. PubMed ID: 25228504
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.
Li C; Wang W; Xie L; Luo X; Cao X; Wan M
Ann N Y Acad Sci; 2016 Jan; 1364(1):62-73. PubMed ID: 25847683
[TBL] [Abstract][Full Text] [Related]
6. A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone.
Khan MP; Mishra JS; Sharan K; Yadav M; Singh AK; Srivastava A; Kumar S; Bhaduaria S; Maurya R; Sanyal S; Chattopadhyay N
Phytomedicine; 2013 Nov; 20(14):1256-66. PubMed ID: 23928508
[TBL] [Abstract][Full Text] [Related]
7. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T
J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454
[TBL] [Abstract][Full Text] [Related]
8. Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo.
Walker EC; Poulton IJ; McGregor NE; Ho PW; Allan EH; Quach JM; Martin TJ; Sims NA
J Bone Miner Res; 2012 Apr; 27(4):902-12. PubMed ID: 22190112
[TBL] [Abstract][Full Text] [Related]
9. Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH(1-34).
Wang L; Quarles LD; Spurney RF
J Bone Miner Res; 2004 Oct; 19(10):1661-70. PubMed ID: 15355561
[TBL] [Abstract][Full Text] [Related]
10. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.
Bellido T; Ali AA; Gubrij I; Plotkin LI; Fu Q; O'Brien CA; Manolagas SC; Jilka RL
Endocrinology; 2005 Nov; 146(11):4577-83. PubMed ID: 16081646
[TBL] [Abstract][Full Text] [Related]
11. Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin.
Bonnet N; Conway SJ; Ferrari SL
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):15048-53. PubMed ID: 22927401
[TBL] [Abstract][Full Text] [Related]
12. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH.
Saini V; Marengi DA; Barry KJ; Fulzele KS; Heiden E; Liu X; Dedic C; Maeda A; Lotinun S; Baron R; Pajevic PD
J Biol Chem; 2013 Jul; 288(28):20122-34. PubMed ID: 23729679
[TBL] [Abstract][Full Text] [Related]
14. Mitogen-activated protein kinase phosphatase 1 regulates bone mass, osteoblast gene expression, and responsiveness to parathyroid hormone.
Mahalingam CD; Datta T; Patil RV; Kreider J; Bonfil RD; Kirkwood KL; Goldstein SA; Abou-Samra AB; Datta NS
J Endocrinol; 2011 Nov; 211(2):145-56. PubMed ID: 21852324
[TBL] [Abstract][Full Text] [Related]
15. Amphiregulin-EGFR signaling mediates the migration of bone marrow mesenchymal progenitors toward PTH-stimulated osteoblasts and osteocytes.
Zhu J; Siclari VA; Liu F; Spatz JM; Chandra A; Divieti Pajevic P; Qin L
PLoS One; 2012; 7(12):e50099. PubMed ID: 23300521
[TBL] [Abstract][Full Text] [Related]
16. Skeletal unloading alleviates the anabolic action of intermittent PTH(1-34) in mouse tibia in association with inhibition of PTH-induced increase in c-fos mRNA in bone marrow cells.
Tanaka S; Sakai A; Tanaka M; Otomo H; Okimoto N; Sakata T; Nakamura T
J Bone Miner Res; 2004 Nov; 19(11):1813-20. PubMed ID: 15476581
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid hormone signaling in mature osteoblasts/osteocytes protects mice from age-related bone loss.
Uda Y; Saini V; Petty CA; Alshehri M; Shi C; Spatz JM; Santos R; Newell CM; Huang TY; Kochen A; Kim JW; Constantinou CK; Saito H; Held KD; Hesse E; Pajevic PD
Aging (Albany NY); 2021 Dec; 13(24):25607-25642. PubMed ID: 34968192
[TBL] [Abstract][Full Text] [Related]
18. Mef2c deletion in osteocytes results in increased bone mass.
Kramer I; Baertschi S; Halleux C; Keller H; Kneissel M
J Bone Miner Res; 2012 Feb; 27(2):360-73. PubMed ID: 22161640
[TBL] [Abstract][Full Text] [Related]
19. Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43.
Chung DJ; Castro CH; Watkins M; Stains JP; Chung MY; Szejnfeld VL; Willecke K; Theis M; Civitelli R
J Cell Sci; 2006 Oct; 119(Pt 20):4187-98. PubMed ID: 16984976
[TBL] [Abstract][Full Text] [Related]
20. The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics.
Lombardi G; Di Somma C; Rubino M; Faggiano A; Vuolo L; Guerra E; Contaldi P; Savastano S; Colao A
J Endocrinol Invest; 2011 Jul; 34(7 Suppl):18-22. PubMed ID: 21985975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
